Latest Bicifadine Stories

2008-10-08 09:00:12

XTL Biopharmaceuticals, a developer of therapeutics for the treatment of diabetic neuropathic pain and hepatitis C virus, has announced that the last patient randomized into the Bicifadine Phase IIb clinical trial for the treatment of diabetic neuropathic pain has completed the study. This milestone officially marks the completion of this randomized, double-blind, placebo-controlled Phase IIb clinical trial which enrolled 351 patients at approximately 40 sites in the US, Germany, Israel and...

2008-08-14 18:00:45

VALLEY COTTAGE, N.Y., Aug. 14 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. today announced that Samuel H. Rudman, Esq., has been appointed to XTL's Board of Directors, effective as of August 13, 2008. Mr. Rudman, 40, is a named partner at a U.S. law firm specializing in complex litigation, emphasizing securities, consumer, insurance, healthcare, human rights, employment discrimination and antitrust class actions. Mr. Rudman's practice is focused primarily on the area of...

2008-07-01 09:01:12

XTL Biopharmaceuticals has completed patient randomization into its Phase IIb study of Bicifadine - a serotonin and norepinephrine reuptake inhibitor - for the treatment of diabetic neuropathic pain. Approximately 350 patients were randomized into the study. Based on the completion of randomization, the company expects to have the last patient complete the study in the next four months. The Phase IIb trial is aimed at demonstrating the efficacy of Bicifadine in diabetic neuropathic pain,...

Word of the Day
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.